These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 11994722)

  • 1. Approaching value in asthma management: the need to integrate clinical and economic research with the basic science.
    Stempel DA; Kelly HW
    J Allergy Clin Immunol; 2002 May; 109(5 Suppl):S503-10. PubMed ID: 11994722
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic analysis of asthma practices.
    Stempel DA
    Am J Manag Care; 2000 Oct; 6(17 Suppl):S930-6; discussion S937-9. PubMed ID: 11184564
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacoeconomics of asthma treatment.
    Cleland J; Thomas M; Price D
    Expert Opin Pharmacother; 2003 Mar; 4(3):311-8. PubMed ID: 12614183
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A cost-effectiveness analysis of first-line controller therapies for persistent asthma.
    Shih YC; Mauskopf J; Borker R
    Pharmacoeconomics; 2007; 25(7):577-90. PubMed ID: 17610338
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Asthma: addressing consistency in results from basic science, clinical trials, and observational experience.
    Spahn J; Covar R; Stempel DA
    J Allergy Clin Immunol; 2002 May; 109(5 Suppl):S490-502. PubMed ID: 11994721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Database studies in asthma pharmacoeconomics: uses, limitations and quality markers.
    Thomas M; Cleland J; Price D
    Expert Opin Pharmacother; 2003 Mar; 4(3):351-8. PubMed ID: 12614187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of an economic model to assess the cost effectiveness of asthma management strategies.
    Price MJ; Briggs AH
    Pharmacoeconomics; 2002; 20(3):183-94. PubMed ID: 11929348
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-utility analysis of the inhaled steroids available in a developing country for the management of pediatric patients with persistent asthma.
    Rodríguez-Martínez CE; Sossa-Briceño MP; Castro-Rodriguez JA
    J Asthma; 2013 May; 50(4):410-8. PubMed ID: 23356720
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of asthma therapy: a comprehensive review.
    Domínguez-Ortega J; Phillips-Anglés E; Barranco P; Quirce S
    J Asthma; 2015; 52(6):529-37. PubMed ID: 25539023
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost effectiveness of asthma management strategies.
    Thomas M; Haughney J; Price D
    Pharmacoeconomics; 2002; 20(11):789. PubMed ID: 12201798
    [No Abstract]   [Full Text] [Related]  

  • 11. Incorporating adherence in cost-effectiveness analyses of asthma: a systematic review.
    Chongmelaxme B; Chaiyakunapruk N; Dilokthornsakul P
    J Med Econ; 2019 Jun; 22(6):554-566. PubMed ID: 30663455
    [No Abstract]   [Full Text] [Related]  

  • 12. Clinical inquiries. Is nedocromil effective in preventing asthmatic attacks in patients with asthma?
    Dudley T; Parker S; Baldwin R
    J Fam Pract; 2004 Nov; 53(11):927-8. PubMed ID: 15527735
    [No Abstract]   [Full Text] [Related]  

  • 13. Measuring costs and consequences in economic evaluation in asthma.
    Sculpher MJ; Price M
    Respir Med; 2003 May; 97(5):508-20. PubMed ID: 12735668
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Medication adherence in asthma therapy--a structured review].
    Fischer J; Wimmer A; Mahlich J
    Pneumologie; 2013 Jul; 67(7):406-14. PubMed ID: 23797492
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimizing the position and use of omalizumab for severe persistent allergic asthma using cost-effectiveness analysis.
    Faria R; McKenna C; Palmer S
    Value Health; 2014 Dec; 17(8):772-82. PubMed ID: 25498772
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [On general practitioners' care of patients with asthma].
    Von Voshaar T; Behr J; Brüggenjürgen B; Deimling A; Krüger M; Virchow C; Wiens C
    MMW Fortschr Med; 2012 Apr; 154 Suppl 1():1-7. PubMed ID: 23427362
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The "e" in cost-effectiveness analyses. A case study of omalizumab efficacy and effectiveness for cost-effectiveness analysis evidence.
    Campbell JD; McQueen RB; Briggs A
    Ann Am Thorac Soc; 2014 Feb; 11 Suppl 2():S105-11. PubMed ID: 24559022
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-leukotriene agents compared to inhaled corticosteroids in the management of recurrent and/or chronic asthma.
    Ducharme FM; Hicks GC
    Cochrane Database Syst Rev; 2000; (3):CD002314. PubMed ID: 10908555
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Pharmacoeconomics of asthma].
    Jahnz-Rózyk K; Targowski T
    Pol Merkur Lekarski; 2004 May; 16 Suppl 1():48-9. PubMed ID: 15524016
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Empowering pharmacists in asthma management through interactive SMS (EmPhAsIS): study protocol for a randomized controlled trial.
    De Vera MA; Sadatsafavi M; Tsao NW; Lynd LD; Lester R; Gastonguay L; Galo J; FitzGerald JM; Brasher P; Marra CA
    Trials; 2014 Dec; 15():488. PubMed ID: 25494702
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.